Phoenix Nest lands $1.49M NIH grant for Sanfilippo syndrome gene therapy
What's the deal? Phoenix Nest, a Brooklyn, New York-based biotech, has received a $1.49 million grant from the National Institute of Neurological Disorders and StrokeDealroom has a profile for this one. Try Dealroom → (NINDS). The award funds manufacturing and analytical development of JLK-247, its gene therapy candidate for Mucopolysaccharidosis Type IIIC (MPS IIIC), also known as Sanfilippo syndrome type C.
Where the money goes: The National Institutes of HealthDealroom has a profile for this one. Try Dealroom → (NIH) SBIR grant will support production of a 500-litre current good manufacturing practice (cGMP) batch of vector ahead of a planned Phase I trial. Most of the work — vector scale-up, analytical assay qualification, and stability and sterility testing — will run through a contract development and manufacturing organisation rather than in-house.
Why it matters: MPS IIIC is caused by a deficiency of the enzyme HGSNAT, which drives heparan sulfate build-up and progressive neurodegeneration in children, with death typically occurring by the mid-30s. The deficient enzyme is membrane-bound within lysosomes, so it cannot be treated with conventional enzyme replacement therapy, leaving gene therapy as one of few viable options.
What's the endgame? There are no approved therapies for MPS IIIC, and Phoenix Nest describes its program as a candidate for the first indication-specific treatment. The company, led by principal investigator Srikanth Singamsetty, has reported a positive prior interaction with the FDA on its clinical development path.
What could go wrong? No clinical efficacy or safety data have yet been generated. The grant covers manufacturing readiness, not the trial itself, so first-in-human dosing remains a step away.
The signal: The award reflects continued NINDS support for late-preclinical manufacturing readiness in rare pediatric neurodegenerative disease — a funding category that has grown as more small biotechs push viral vector programs toward IND filing.
Read more: AllSci
Image credit: Generated with Gemini
